Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

AK0610 is engineered from an antibody isolated from a recovered infant and targets the pre-fusion F protein of RSV.

Rallybio (RLYB) announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and ...

(“ArkBio”) announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a ...

Charnelda G. Ruffin, Pharm.D., is Clinical Pharmacy Specialist, Kaiser Permanente, Atlanta, GA; at the time of writing she was Clinical Information Pharmacist, ACS State Healthcare, Atlanta ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

Rallybio Corporation , a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication ...

LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.

An increase in research and development (R&D) activities in myotonic dystrophy is expected to drive market growth by ...

After hours: November 22 at 7:54 PM EST Loading Chart for IMAB ...

The phase 1/3 ROSALIA study showed that the copycat denosumab matched Amgen's brand on multiple pharmacokinetics ... (romosozumab), an anti-sclerostin antibody that was approved for postmenopausal ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...